The Effect of Metformin on the Proliferation, Apoptosis and CD133 mRNA Expression of Colon Cancer Stem Cells by Upregulation of miR 342-3p

References

• BeagleyJ, GuariguataL, WeilC, MotalaAA. Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract. 2014;103(2):150–160. doi:10.1016/j.diabres.2013.11.00124300018
   PubMed Web of Science ®Google Scholar
• GakidouE, MallingerL, Abbott-KlafterJ, et al. Management of diabetes and associated cardiovascular risk factors in seven countries: a comparison of data from national health examination surveys. Bull World Health Organ. 2011;89(3):172–183.21379413
   PubMed Web of Science ®Google Scholar
• HanK, XiYF, WangWR. Epidemiological investigation of diabetes and impaired fasting blood glucose among Mongolian residents over 35 years old in Inner Mongolia Autonomous Region. J Chronic Dis. 2018;19(01):8–11.
   Google Scholar
• KaiF. Epidemiological status and risk factors of diabetes and impaired fasting blood glucose among residents aged 40-79 in Beijing. Chin General Pract. 2019;22:1014–1020.
   Google Scholar
• LiqunL. Epidemiological investigation and risk factor analysis of adult diabetes in Jiangxi Province. Jiangxi Med. 2019;54(1143–1147):1153.
   Google Scholar
• HemminkiK, LiX, SundquistJ, SundquistK. Risk of cancer following hospitalization for type 2 diabetes. Oncologist. 2010;15(6):548–555.20479278
   PubMed Web of Science ®Google Scholar
• GiovannucciE, MichaudD. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007;132(6):2208–2225.17498513
   PubMed Web of Science ®Google Scholar
• HjartåkerA, LangsethH, WeiderpassE. Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol. 2008;630:72–93.18637486
   PubMed Web of Science ®Google Scholar
• WojciechowskaJ, KrajewskiW, BolanowskiM, KręcickiT, ZatońskiT. Diabetes and Cancer: a Review of Current Knowledge. Exp Clin Endocrinol Diabetes. 2016;124(5):263–275.27219686
   PubMed Web of Science ®Google Scholar
• ZhouXH, QiaoQ, ZetheliusB, et al. Diabetes, prediabetes and cancer mortality. Diabetologia. 2010;53(9):1867–1876.20490448
   PubMed Web of Science ®Google Scholar
• SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.33538338
   PubMed Web of Science ®Google Scholar
• SiegelRL, MillerKD, Goding SauerA, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–164.32133645
   PubMed Web of Science ®Google Scholar
• van de Poll-franseLV, HoutermanS, Janssen-HeijnenML, DercksenMW, CoeberghJW, HaakHR. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int j Cancer. 2007;120(9):1986–1992.17230509
   PubMed Web of Science ®Google Scholar
• ZhangZJ, ZhengZJ, KanH, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care. 2011;34(10):2323–2328.21949223
   PubMed Web of Science ®Google Scholar
• ZhaoX, LiY, ChenM, et al. Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance. Eur J Cancer Prev. 2015;24(1):27–36.25162967
   PubMed Web of Science ®Google Scholar
• GongJ, KelekarG, ShenJ, ShenJ, KaurS, MitaM. The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development. Target Oncol. 2016;11(4):447–467.26864078
   PubMed Web of Science ®Google Scholar
• FedyaninM, AnnaP, ElizavetaP, SergeiT. Role of stem cells in colorectal cancer progression and prognostic and predictive characteristics of stem cell markers in colorectal cancer. Curr Stem Cell Res Ther. 2017;12(1):19–30.27593447
   PubMed Web of Science ®Google Scholar
• RaoM, GaoC, GuoM, LawBYK, XuY. Effects of metformin treatment on radiotherapy efficacy in patients with cancer and diabetes: a systematic review and meta-analysis. Cancer Manag Res. 2018;10:4881–4890.30425579
   PubMed Web of Science ®Google Scholar
• TomasettiC, VogelsteinB. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science (New York, NY). 2015;347(6217):78–81.
   Google Scholar
• YuZ, ZhaoG, LiP, et al. Temozolomide in combination with metformin act synergistically to inhibit proliferation and expansion of glioma stem-like cells. Oncol Lett. 2016;11(4):2792–2800.27073554
   PubMed Web of Science ®Google Scholar
• ShiP, LiuW. Tala, et al. Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discovery. 2017;3:17010.28480051
   PubMed Web of Science ®Google Scholar
• CourtoisS, DuránRV, GiraudJ, et al. Metformin targets gastric cancer stem cells. Eur J Cancer. 2017;84:193–201.28822889
   PubMed Web of Science ®Google Scholar
• YinAH, MiragliaS, ZanjaniED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90(12):5002–5012.9389720
   PubMed Web of Science ®Google Scholar
• KloseJ, EisseleJ, VolzC, et al. Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/β-catenin signaling in CD133(+) human colorectal cancer cells. BMC Cancer. 2016;16(1):896.27855654
   PubMed Web of Science ®Google Scholar
• TangY, BerlindJ, MavilaN. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells. Cell Commun Signal. 2018;16(1):9.29530069
   PubMed Web of Science ®Google Scholar
• KhanAQ, AhmedEI, ElareerNR, JunejoK, SteinhoffM, UddinS. Role of miRNA-regulated cancer stem cells in the pathogenesis of human malignancies. Cells. 2019;8:8.
   Web of Science ®Google Scholar
• JiangL, HermekingH. miR-34a and miR-34b/c suppress intestinal tumorigenesis. Cancer Res. 2017;77(10):2746–2758.28363996
   PubMed Web of Science ®Google Scholar
• EbrahimiF, GopalanV, WahabR, LuCT, SmithRA, LamAK. Deregulation of miR-126 expression in colorectal cancer pathogenesis and its clinical significance. Exp Cell Res. 2015;339(2):333–341.26455548
   PubMed Web of Science ®Google Scholar
• YangF, XieYQ, TangSQ, WuXB, ZhuHY. miR-143 regulates proliferation and apoptosis of colorectal cancer cells and exhibits altered expression in colorectal cancer tissue. Int J Clin Exp Med. 2015;8(9):15308–15312.26629019
   PubMed Web of Science ®Google Scholar
• ShengN, TanG, YouW, et al. MiR-145 inhibits human colorectal cancer cell migration and invasion via PAK4-dependent pathway. Cancer Med. 2017;6(6):1331–1340.28440035
   PubMed Web of Science ®Google Scholar
• WangH, WuJ, MengX, et al. MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis. 2011;32(7):1033–1042.21565830
   PubMed Web of Science ®Google Scholar
• BaoB, WangZ, AliS, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res. 2012;5(3):355–364.
   PubMed Web of Science ®Google Scholar
• ZhangQ, ChenM, ZhaoX, WangL. Preliminary study of the effects of metformin on proliferation, apoptosis and the expression of CD133 in colon cancer stem cells. Chin J Diabetes. 2017;25:639–643.
   Google Scholar
• ZhouQ, ChenA, SongH, TaoJ, YangH, ZuoM. Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis. Int J Clin Exp Med. 2015;8(3):3080–3088.26064196
   PubMed Web of Science ®Google Scholar
• Ricci-VitianiL, LombardiDG, PilozziE, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–115.17122771
   PubMed Web of Science ®Google Scholar
• LiuC, KelnarK, LiuB, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17(2):211–215.21240262
   PubMed Web of Science ®Google Scholar
• HaoJ, ZhaoS, ZhangY, et al. Emerging role of microRNAs in cancer and cancer stem cells. J Cell Biochem. 2014;115(4):605–610.24166873
   PubMed Web of Science ®Google Scholar
• LiuY, ZhangB, WenC, et al. [Overexpressed miRNA-134b inhibits proliferation and invasion of CD133(+) U87 glioma stem cells]. Xi bao yu Fen Zi Mian Yi Xue Za Zhi/Chin J Cell Mol Immunol. 2017;33(5):637–642. Chinese.
   PubMedGoogle Scholar
• HuangSX, ZhaoZY, WengGH, et al. Upregulation of miR-181a suppresses the formation of glioblastoma stem cells by targeting the Notch2 oncogene and correlates with good prognosis in patients with glioblastoma multiforme. Biochem Biophys Res Commun. 2017;486(4):1129–1136.28389242
   PubMed Web of Science ®Google Scholar
• Nangia-MakkerP, YuY, VasudevanA, et al. Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One. 2014;9(1):e84369.24465408
   PubMed Web of Science ®Google Scholar
• YangS, LiY, GaoJ, et al. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene. 2013;32(36):4294–4303.23001043
   PubMed Web of Science ®Google Scholar
• YamamuraS, SainiS, MajidS, et al. MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS One. 2012;7(1):e29722.22235332
   PubMed Web of Science ®Google Scholar
• ChiyomaruT, TataranoS, KawakamiK, et al. SWAP70, actin-binding protein, function as an oncogene targeting tumor-suppressive miR-145 in prostate cancer. Prostate. 2011;71(14):1559–1567.21360565
   PubMed Web of Science ®Google Scholar
• SpizzoR, NicolosoMS, LupiniL, et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ. 2010;17(2):246–254.19730444
   PubMed Web of Science ®Google Scholar
• KanoM, SekiN, KikkawaN, et al. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010;127(12):2804–2814.21351259
   PubMed Web of Science ®Google Scholar
• SlabyO, SvobodaM, FabianP, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007;72(5–6):397–402.18196926
   PubMed Web of Science ®Google Scholar
• TaiHC, ChangAC, YuHJ, et al. Osteoblast-derived WNT-induced secreted protein 1 increases VCAM-1 expression and enhances prostate cancer metastasis by down-regulating miR-126. Oncotarget. 2014;5(17):7589–7598.25277191
   PubMedGoogle Scholar
• LiXR, ChuHJ, LvT, WangL, KongSF, DaiSZ. miR-342-3p suppresses proliferation, migration and invasion by targeting FOXM1 in human cervical cancer. FEBS Lett. 2014;588(17):3298–3307.25066298
   PubMed Web of Science ®Google Scholar
• KomollRM, HuQ, OlarewajuO, et al. MicroRNA-342-3p is a potent tumor suppressor in hepatocellular carcinoma. J Hepatol. 2021;74(1):122–134.32738449
   PubMed Web of Science ®Google Scholar
• TaoK, YangJ, GuoZ, et al. Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer. Am J Transl Res. 2014;6(4):391–401.25075256
   PubMed Web of Science ®Google Scholar
• LindholmEM, LeivonenSK, UndlienE, et al. miR-342-5p as a potential regulator of HER2 breast cancer cell growth. MicroRNA (Shariqah, United Arab Emirates). 2019;8(2):155–165.
   PubMedGoogle Scholar
• LiuQ, WangZ, ZhouX, et al. miR-342-5p inhibits osteosarcoma cell growth, migration, invasion, and sensitivity to Doxorubicin through targeting Wnt7b. Cell Cycle (Georgetown, Tex). 2019;18(23):3325–3336.
   PubMed Web of Science ®Google Scholar
• YangH, LiQ, NiuJ, et al. microRNA-342-5p and miR-608 inhibit colon cancer tumorigenesis by targeting NAA10. Oncotarget. 2016;7(3):2709–2720.26646451
   PubMedGoogle Scholar
• ZampetakiA, KiechlS, DrozdovI, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107(6):810–817.20651284
   PubMed Web of Science ®Google Scholar
• JiangZH, TangYZ, SongHN, YangM, LiB, NiCL. miRNA‑342 suppresses renal interstitial fibrosis in diabetic nephropathy by targeting SOX6. Int J Mol Med. 2020;45(1):45–52.31746345
   PubMed Web of Science ®Google Scholar